Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00696176 · ClinicalTrials.gov registry record · Early Phase 1
STAT3 DECOY in Head and Neck Cancer
A Early Phase 1 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 32
- Enrollment target
NCT00696176 is a Early Phase 1 study that has completed, run by University of Pittsburgh. The registered enrollment target is 32 participants.
The verdict
NCT00696176, a Early Phase 1 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The primary goal of this study is to evaluate the safety of a transcription factor decoy targeting Signal Transducer and Activator of Transcription 3(STAT3) in patients with head and neck cancer. The rationale for targeting STAT3 using this approach is to decrease STAT3-mediated gene regulation. The study has the following scientific objectives: 1. To assess the safety of a single dose of intratumoral STAT3 decoy. 2. To estimate the effect of STAT3 decoy therapy on STAT3 activation levels, STAT3-mediated gene expression, and apoptosis in treated tumors.
Interventions
- DRUG STAT 3 DECOY
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-08 |
| Est. Completion | 2011-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00696176
The ClinicalTrials.gov registry entry for NCT00696176 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STAT 3 DECOY is the first listed.
NCT00696176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00696176 about?
NCT00696176 is a clinical study titled "STAT3 DECOY in Head and Neck Cancer". The primary goal of this study is to evaluate the safety of a transcription factor decoy targeting Signal Transducer and Activator of Transcription 3(STAT3) in patients with head and neck cancer. The rationale for targeting STAT3 using this approach is to decrease STAT3-mediated gene regulation. The...
What is the current status of trial NCT00696176?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 32 participants. The study started on 2008-08. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00696176?
The interventions under investigation include: STAT 3 DECOY (DRUG).
Who is sponsoring clinical trial NCT00696176?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.